Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Shenzhen - Delayed Quote CNY

Xiangxue Pharmaceutical Co.,Ltd. (300147.SZ)

Compare
6.02
+0.18
+(3.08%)
At close: 3:04:22 PM GMT+8
Loading Chart for 300147.SZ
  • Previous Close 5.84
  • Open 6.20
  • Bid 6.03 x --
  • Ask 6.04 x --
  • Day's Range 5.80 - 6.09
  • 52 Week Range 3.16 - 16.49
  • Volume 24,995,944
  • Avg. Volume 35,088,243
  • Market Cap (intraday) 3.981B
  • Beta (5Y Monthly) 0.46
  • PE Ratio (TTM) --
  • EPS (TTM) -0.70
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jun 23, 2020
  • 1y Target Est --

Xiangxue Pharmaceutical Co., Ltd. engages in the research and development, procurement, manufacture, delivery, and distribution of pharmaceutical products in China. It offers antivirotic oral liquids under the Xiangxue brand name; and healthcare supplements, as well as health solutions, such as food and beverage. Xiangxue Pharmaceutical Co., Ltd. has strategic partnership agreement with 111, Inc. to develop the Internet + Medicine model for China's traditional Chinese medicine industry. Xiangxue Pharmaceutical Co., Ltd. was founded in 1997 and is based in Guangzhou, China.

www.xphcn.com

2,644

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 300147.SZ

View More

Performance Overview: 300147.SZ

Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

300147.SZ
38.38%
SSE Composite Index (000001.SS)
0.29%

1-Year Return

300147.SZ
41.98%
SSE Composite Index (000001.SS)
8.89%

3-Year Return

300147.SZ
20.48%
SSE Composite Index (000001.SS)
1.81%

5-Year Return

300147.SZ
30.48%
SSE Composite Index (000001.SS)
20.91%

Compare To: 300147.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 300147.SZ

View More

Valuation Measures

Annual
As of 4/2/2025
  • Market Cap

    3.86B

  • Enterprise Value

    6.12B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.82

  • Price/Book (mrq)

    2.26

  • Enterprise Value/Revenue

    2.91

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -21.89%

  • Return on Assets (ttm)

    -0.63%

  • Return on Equity (ttm)

    -19.45%

  • Revenue (ttm)

    2.1B

  • Net Income Avi to Common (ttm)

    -460.69M

  • Diluted EPS (ttm)

    -0.70

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    75.6M

  • Total Debt/Equity (mrq)

    110.24%

  • Levered Free Cash Flow (ttm)

    -380.88M

Research Analysis: 300147.SZ

View More

Company Insights: 300147.SZ

Research Reports: 300147.SZ

View More

People Also Watch